Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia

Zoe K. McQuiltenab* , Ljoudmila Busijaa, John F. Seymourcd , Simon Stanworthefg, Erica M. Woodab , Melita Kenealyhi, Robert Weinkovejkl & on behalf of the Australasian Leukaemia and Lymphoma Group (ALLG)a Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australiab Department of Haematology, Monash Health, Melbourne, Australiac Department of Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Australiad Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australiae Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UKf Clinical Department, NHS Blood and Transplant, Oxford, UKg Radcliffe Department of Medicine, University of Oxford, and NIHR Oxford Biomedical Research Centre, Oxford, UKh Cabrini Health, Melbourne, Australiai Faculty of Medicine Nursing and Health Sciences, Monash University, Melbourne, Australiaj Wellington Blood & Cancer Centre, Capital & Coast District Health Board, Wellington, New Zealandk Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealandl Department of Pathology and Molecular Medicine, University of Otago Wellington, Wellington, New Zealand